

AMENDMENT UNDER 37 C.F.R. § 1.111
Application No. 10/812,357

Attorney Docket A8739

AMENDMENTS TO THE CLAIMS


This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1.-15. (Canceled)

16. (Currently amended) A kit for diagnosing prostate cancer, comprising:

(a) an isolated antibody raised against~~At least one moiety that specifically binds to~~
RM2 antigen, wherein said RM2 antigen comprises~~having the epitope~~ structure shown below,
~~from a specimen obtained from a patient suspected of having prostate cancer:~~



wherein R represents a carrier,

(b) instructions~~Instructions~~ for diagnosing prostate cancer using said kit, and

(c) ~~Optionally~~optionally, a means for detecting binding between said antibody and RM2
antigen in a patient sample~~the presence of said antigen by specific binding of said moiety to said~~
~~antigen.~~

17. (Canceled)

18. (Original) The kit of claim 16, wherein said antibody is selected from the group consisting of a polyclonal antibody, a single chain polyclonal antibody, a polyclonal antibody fragment, a monoclonal antibody, a single chain monoclonal antibody, a monoclonal antibody fragment, a chimeric antibody, a single chain chimeric antibody, a chimeric antibody fragment, a resurfaced antibody, a resurfaced single chain antibody, a resurfaced antibody fragment, a humanized antibody, a humanized single chain antibody, and a humanized antibody fragment.

19. (Canceled).

20. (Currently amended) The kit of claim 16, wherein said antibody moiety that specifically binds to said RM2 antigen is a monoclonal antibody.

21. (Currently amended) The kit of claim 16, wherein said antibody raised against said RM2 antigen moiety that specifically binds to said RM2 antigen is directed to the epitope recognized by RM2 monoclonal antibody.

22.-33. (Canceled).

34. (New) The kit of claim 16, wherein R is lactosamine chain N-linked or O-linked to glycoprotein, or 4Glc β 1-1Cer in glycosphingolipid.

35. (New) The kit of claim 16, wherein R is a synthetic carrier molecule.
36. (New) The kit of claim 16, wherein R is a naturally-occurring carrier molecule.
37. (New) The kit of claim 16, wherein said RM2 antigen is isolated from a prostate cancer patient.